Eversept Partners’s Cytokinetics CYTK Stock Holding History

Eversept Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$208K	–	93
2020 Q4	$208K	Buy	+10,000	New	+$183K	0.02%	61

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Eversept Partners's CYTK Position: Q3 2024 in Review

Eversept Partners sold out of Cytokinetics (CYTK) in Q3 2024, closing a stake of 126,877 shares — an estimated $6.87M sold.

Eversept Partners first reported a position in CYTK in Q3 2019 and held it in 5 quarters. The position peaked at $6.87M in Q2 2024. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

Eversept Partners reported no remaining Cytokinetics position as of Q3 2024 after selling out during the quarter.
Eversept Partners sold 126,877 Cytokinetics shares in Q3 2024, an estimated $6.87M.
Eversept Partners first reported a position in Cytokinetics in Q3 2019 and held it in 5 quarters.
Eversept Partners's Cytokinetics position peaked at $6.87M in Q2 2024.
347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.